logo
They helped Democrats win back the House in 2018. Now they're taking on a new mission

They helped Democrats win back the House in 2018. Now they're taking on a new mission

CNN4 days ago

In 2018, Democrats won back the House — ending eight years of Republican control — with the help of dozens of candidates with national security backgrounds who vowed to serve as a check against the first Trump administration.
This year, two of those successful candidates — Virginia's Abigail Spanberger and New Jersey's Mikie Sherrill — are taking on a new challenge following President Donald Trump's return to power: running for governor.
As Democrats grapple with how best to improve their diminished standing with voters, the upcoming races for governor in Virginia and New Jersey will serve as crucial tests for the party ahead of the 2026 midterm elections. Spanberger's and Sherrill's campaigns could offer critical clues to next year's candidates as they seek to understand the mood of the electorate a year after Trump's 2024 victory.
The two candidates — and former Capitol Hill roommates — are facing vastly different races.
Sherrill is one of half a dozen candidates seeking to portray themselves as the Democratic fighter best positioned to take on the eventual Republican nominee and the Trump administration ahead of a June 10 primary. One recent Sherrill ad warns that Jack Ciattarelli, who was endorsed by Trump this month, will bring the president's 'MAGA agenda' to the state. The spot highlights Sherrill's record as a Navy pilot and federal prosecutor and describes her as the Democrat 'Republicans fear.'
Spanberger — who, like her Republican opponent, Lt. Gov. Winsome Earle-Sears, is running unopposed — is directing much of her focus toward criticizing the record of outgoing Republican Gov. Glenn Youngkin. The former CIA intelligence officer has hammered Earle-Sears and Youngkin over their response to the Department of Government Efficiency as the Elon Musk-led effort aims to shrink the size of the federal workforce that employs more than 300,000 Virginians.
Spanberger, who did not run for reelection in the House last year, and Sherrill, who held on to her seat, are portraying themselves as results driven and willing to buck their party if necessary.
'People can label me however they want as a question of policy, but I think what is the most substantial characteristic that I ascribe to myself is pragmatic,' Spanberger told CNN in an interview earlier this year. 'Throughout my time in Congress, my frustration — when I had expressed it at various different points in time — was rooted in that pragmatism.'
They are also testing out ways to message on economic concerns, an area where Trump held a significant advantage among voters last November but has seen some erosion amid his trade war. They're also acknowledging that, if they're elected in these new roles, they would be in a much better position to impact the lives of a larger swath of people.
'At this moment, the fight is really in the states, that's where the front line is,' Sherrill told CNN after a campaign event in Elizabeth, New Jersey. 'It's going to be strong Democratic governors who can best help the nation.'
Sherrill said Democrats need to build the party from the ground up by 'taking an expansive view of state power' as they push to make life more affordable for voters and run effective governments. Even as Democrats are working to counter Trump administration policies, the party must continue to keep a focus on kitchen-table issues, she said.
'Sometimes we get caught up in some of the concerns we have — which are huge, huge concerns — about what's coming up in Washington, but don't always remind people of the work we're doing to drive down costs,' Sherrill said.
Democrats flipped 41 House seats in the 2018 midterm elections and elected 67 new members overall. Three cycles later, about half of them are still in office. Several have already sought higher office.
Andy Kim of New Jersey and Elissa Slotkin of Michigan were both elected to the US Senate, while former Reps. Colin Allred of Texas, Debbie Mucarsel-Powell of Florida and Katie Porter of California lost Senate bids last year.
A handful are also running in primaries ahead of next year's midterm elections. Former Interior Secretary and New Mexico Rep. Deb Haaland is running for governor in her state, as is Porter. Reps. Chris Pappas of New Hampshire, Haley Stevens of Michigan and Angie Craig of Minnesota are all running for Senate.
Dan Sena, the executive director of House Democrats' campaign arm during the 2018 cycle, described the candidates who ran then as 'independent, country first-driven' leaders who at times stood up to their own party. Sena, who is now working with an outside group supporting Sherrill's campaign, said Democrats should look to the 2018 recruiting formula next year.
'They should be looking for candidates that can support the Democratic Party but look and feel like a different type of Democrat: a Democrat with a record of service, a Democrat that's a patriot, a Democrat that puts their country first,' he said.
Virginia and New Jersey shifted toward Trump during the 2024 election, but history suggests political headwinds are likely to favor Democrats in the upcoming gubernatorial races. Over the last several decades both states have elected candidates from the party that lost the White House the year before, with two exceptions: Democrat Terry McAuliffe won the 2013 Virginia governor's race after President Barack Obama was reelected, and Democratic New Jersey Gov. Phil Murphy was reelected in 2021 after President Joe Biden won in 2020.
Both seats are open due to the incumbents being term-limited.
Democrats are also hoping to capitalize on high-profile Republican legislation, just as they did in 2018 when Democratic candidates blasted their opponents over their votes backing a failed effort to repeal the Affordable Care Act. This time around, Democrats are pointing to the sweeping tax and spending cuts proposal House Republicans passed last week, which would add work requirements to Medicaid and make deep cuts to food stamps.
'Winning these campaigns is really about being able to explain to voters the ways in which these candidates are going to stand up for them and fight for them,' said Jessica Mackler, the president of EMILY's List, which works to elect women who support abortion rights and has long backed Spanberger and Sherrill.
Republicans have started preparing their own messaging on the bill, arguing that provisions like no taxes on tips are popular, and that the restrictions on Medicaid benefits will sustain the program for those who need it most.
'It's going to be imperative you tie them to national trends that are potentially negative in party politics that they're going to have to deal with in both New Jersey and Virginia,' one GOP strategist who has worked on House campaigns said of Spanberger and the eventual Democratic nominee in New Jersey.
Spanberger and the field of New Jersey Democratic gubernatorial candidates are attempting to rehabilitate the party's brand when it comes to economic issues. Or, at the very least, not be associated with it.
Patricia Campos-Medina, a labor leader and former New Jersey US Senate candidate backing Sherrill, said affordability is the No. 1 issue for Garden State voters — including housing, transportation and energy bill costs.
'That's how we counteract this idea that Trump and the Republicans are the only ones who care about the economy and your job,' Campos-Medina said. 'Democrats care about the economy and jobs and housing and schools and transportation, and that's the message that's going to resonate.'
At events in northern New Jersey, Sherrill repeatedly pointed to her proposals to build more residences to reduce housing costs.
At a recent campaign event at a family-owned drugstore in Mechanicsville, a small, Republican-leaning town outside Richmond, Spanberger laid out her plan to lower health care and prescription drug costs. She also referenced the influence that health care issues had on her decision to first run for Congress.
'Back in 2017 I watched my member of Congress vote to repeal the Affordable Care Act,' Spanberger said. 'It was then that I knew that I needed to run against him.'
As she highlighted her plan to boost the affordability of Virginia's health care as governor, Spanberger said she saw similarities between the 2017 health care debate and the current fight over the far-reaching domestic policy bill.
'Now, unfortunately, we're seeing much of the same, which is an effort to further degrade a health care system that very frankly and objectively needs improvements,' Spanberger told reporters.
In interviews, Democratic primary voters in both New Jersey and Virginia said they were looking for governors who would serve as a check on the Trump administration. Many expressed frustrations with the Democratic Party, which they said either did not have a clear, unifying message or needed to focus more on affordability issues.
Mary Butler, a 74-year-old retired social worker from Mechanicsville who attended Spanberger's speech and plans to support her in November, said health care access was deeply important to her because she saw how a lack of access could impact her former clients. Asked to assess national Democrats' performance, she said the party's vision wasn't being communicated well.
'Why isn't there a really strong message being given — one clear, strong message?' Butler said. 'It's a real question mark for me, I don't understand it.'
At a campaign stop over Memorial Day weekend, Sherrill gave her stump speech and took questions from a few dozen voters at a pizza shop in Jersey City, where one primary opponent, Steven Fulop, serves as mayor. The questions focused on housing costs, education and how Sherrill, as governor, would respond to parts of the president's agenda, such as immigration.
Sherrill criticized Republicans, from Ciattarelli to members of Congress, for not pushing back on the president. She likened them to sailors on a ship ignoring impending danger for fear of reprisal over speaking out.
'A lesson I learned in the Navy: The worst thing you can do is to run a ship aground,' Sherrill said. 'And you find when you do that, that people on that ship know it's going to run aground, and they don't say anything because they're scared.'
Susan Murphy, a 57-year-old retired theater teacher and Jersey City native, said she will vote for whoever wins the Democratic nomination, but she thought Sherrill seemed to be the strongest to go up against a 'MAGA Republican.' She said she viewed Democratic governors as a check on the administration and wondered why national leaders in her party seemed unprepared to take on the Trump administration at the start of his term.
'I know that their hands are tied in terms of holding Trump accountable in many ways,' she said. 'My problem is, why weren't they ready? Why did it take so long?'
David Patel, a 59-year-old business owner from Jersey City who is backing Sherrill, said Democrats 'need to learn what people want.'
He said he sometimes gets frustrated with what he described as his party's tendency to focus on issues 'that don't matter.' Asked what those issues are, he instead pointed to what he would like to hear about: health care, job creation and training, and education.
He said he hoped losing the presidential election would get the party back on track: 'I think they got the message.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Which Class of ER Degrader Is Better?
Which Class of ER Degrader Is Better?

Medscape

time9 minutes ago

  • Medscape

Which Class of ER Degrader Is Better?

Vepdegestrant, an investigational estrogen receptor (ER) degrader, known as a proteolysis-targeting chimera (PROTAC ), outshone the commonly used selective estrogen receptor degrader (SERD) fulvestrant in a phase 3 trial of second-line treatment for a subset of patients with breast cancer. The VERITAC-2 trial included patients with ER-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-), locally advanced or metastatic disease who had failed prior treatment with cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors and endocrine therapy, and no exposure to chemotherapy in the advanced setting. Only a subset of the study cohort, those with estrogen receptor 1-mutant disease, experienced a statistically significant and clinically meaningful improvement in progression-free survival (PFS) when treated with vepdegestrant compared with patients treated with fulvestrant. 'These results support vepdegestrant as a potential monotherapy treatment option for patients with previously treated ESR1 -mutant ER+/HER2- advanced breast cancer,' said lead author Erika P. Hamilton, MD, a medical oncologist and director of Breast Cancer and Gynecologic Cancer Research at Sarah Cannon Research Institute, Nashville, Tennessee, during a press conference for the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The findings were simultaneously published in the New England Journal of Medicine . Vepdegestrant is not approved by the US Food and Drug Administration, but received fast-track status in February 2024 as monotherapy for this patient population. It is the first and only PROTAC ER degrader to be evaluated in a phase 3 clinical trial in breast cancer. PROTACs represent a novel class of therapeutic agents that harness the proteasome to selectively degrade target proteins. 'There's no established consensus for patients getting treatment in the second-line setting after progression on endocrine therapy and a CDK 4/6 inhibitor,' explained Hamilton. 'One of the mainstays of our treatment really has been fulvestrant, which clearly has some challenges. First, it's administered intramuscularly, and second, in a post-CDK 4/6 landscape, we know that progression-free survival is very short — on the order of less than 2 months.' Besides fulvestrant, the oral SERD elacestrant was FDA-approved in January 2023, and other oral SERDs are in development, she noted. Trial Design The new trial included 624 patients with advanced ER+/HER2- disease that had progressed following one or two lines of endocrine therapy and a CDK 4/6 inhibitor. 'They could not have received fulvestrant already or chemotherapy, and patients had to have benefited from their previous line of endocrine therapy for at least 6 months to enter the study,' Hamilton noted. Study participants were also stratified by the presence or absence of visceral disease, as well as the presence of an ESR1 mutation (n = 270). Such mutations are a common cause of acquired resistance found in approximately 40% of patients in the second-line setting, according to a press release from the drug developer. Patients were randomly assigned 1:1 to 28-day treatment cycles of either 200 mg oral vepdegestrant once daily, or 500 mg intramuscular fulvestrant on day 1 and day 15 of the first cycle, and then on day 1 of each subsequent cycle. The primary endpoint was PFS by blinded, independent central review, first in patients with ESR1 mutations and then in the entire cohort. Key secondary endpoints were overall survival, objective response rate, and clinical benefit rate, which was defined as the rate of confirmed clinical or partial response at any time, or stable disease, nonclinical response, or nonprogressive disease for at least 24 weeks. Vepdegestrant vs Fulvestrant The study met its key primary endpoint, showing a median PFS of 5.0 months with vepdegestrant compared with 2.1 months with fulvestrant (hazard ratio [HR] 0.57; P < .001) in the 270 patients with ESR1 mutations. At 6 months, twice as many patients in the vepdegestrant arm remained progression-free compared with those in the fulvestrant arm (45.2% vs 22.7%). However, this primary endpoint was not significantly different between groups when calculated for the entire patient population (HR, 0.83; P = .07). For the key secondary endpoints, among patients with ESR1 mutations, the clinical benefit rate was more than double in patients receiving vepdegestrant (42.1% vs 20.2%). Similarly, the objective response rate was more than four times higher (18.6% vs 4%) Commenting in a press release, ASCO breast cancer expert Jane Lowe Meisel, MD, said that although the trial found that vepdegestrant worked better than fulvestrant in patients with ESR1 mutations, 'on average, patients did not have prolonged responses on either agent, highlighting the need for combination therapies and continued development in this space.' Meisel is co-director of Breast Medical Oncology at the Winship Cancer Institute of Emory University School of Medicine in Atlanta, Georgia. 'Overall survival was very immature at the time of this analysis, with only 20% of the anticipated events occurring,' added lead investigator Hamilton. Treatment-emergent adverse events (TEAEs) led to discontinuation in 3% of patients taking vepdegestrant and 1% of patients taking fulvestrant. TEAEs leading to dose reductions occurred in 2% of the vepdegestrant group and none in the fulvestrant group. The three most common AEs of any grade were fatigue (27% in vepdegestrant group, 16% fulvestrant group) and increased aspartate aminotransferase and alanine aminotransferase levels of any grade (14% vepdegestrant group, 10% fulvestrant group). Oral SERDS vs Vepdegestrant Side Effects Compared to oral SERDs, vepdegestrant has a favorable side effect profile, Hamilton said. 'Oral SERDs have prominent GI side effects as their most frequent side effect.' But, across all grades, rates of both vomiting and diarrhea were only 6% with vepdegestrant. GI side effects tend to be more common, 'in the 30% or 40% range with oral SERDs,' she told Medscape Medical News . Study discussant William John Gradishar, MD, emphasized the importance of reducing side effects. ' Vepdegestrant now joins a growing list of drugs that perform better than current standard of care monotherapy' in the ESR1 -mutant population, he noted in the session. But the reality is that most of these drugs are being developed to be used in combination with targeted therapies, 'and increased toxicity can be expected with doublet therapy…Quality of life measures as experienced and reported by patients are critical, and even modest changes in symptom and functional domains should not be minimized,' said Gradishar, professor of breast oncology at Northwestern University Feinberg School of Medicine, Chicago, Illinois. 'Vepdegestrant has demonstrated compelling preclinical activity and encouraging early clinical data supporting its efficacy in degrading ER,' said Albert Grinshpun, MD, in an interview with Medscape Medical News . Grinshpun, head of the Breast Cancer Service at Shaare Zedek Medical Center and The Hebrew University, Jerusalem, Israel, said his initial takeaway from the study is that 'vepdegestrant now stands alongside other oral SERDs, such as elacestrant and imlunestrant, in demonstrating superiority over fulvestrant, specifically in the context of ESR1­ -mutant [disease].' 'Importantly, the treatment landscape for patients progressing on CDK 4/6 inhibitors is rapidly evolving, with a growing shift toward combination therapies rather than fulvestrant monotherapy,' he said. 'In my view, vepdegestrant has established itself as a promising endocrine backbone for future combination strategies. Its favorable toxicity profile makes it particularly well-suited for pairing with a range of targeted agents or even antibody-drug conjugates, including inhibitors of PIK3CA and KAT6 , in the pursuit of more effective therapeutic regimens.' The study was jointly funded by Arvinas Estrogen Receptor, Inc. and Pfizer. Hamilton disclosed consulting or advisory roles with Accutar Biotechnology (Inst), Arvinas (Inst), AstraZeneca (Inst), Circle Pharma (Inst), Daiichi Sankyo (Inst), Ellipses Pharma (Inst), Entos (Inst), Fosun Pharma (Inst), Genentech/Roche (Inst), Gilead Sciences (Inst), Janssen (Inst), Jazz Pharmaceuticals (Inst), Jefferies (Inst), Johnson & Johnson (Inst), Lilly (Inst), Medical Pharma Services (Inst), Mersana (Inst), Novartis (Inst), Olema Pharmaceuticals (Inst), Pfizer (Inst), Stemline Therapeutics (Inst), Tempus (Inst), Theratechnologies (Inst), Tubulis GmbH (Inst), Verascity Science (Inst), and Zentalis (Inst). Hamilton has also received research funding from AbbVie (Inst), Accutar Biotech (Inst), Acerta Pharma (Inst), ADC Therapeutics (Inst), Akeso Biopharma (Inst), Amgen (Inst), Aravive (Inst), ArQule (Inst), Artios (Inst), Arvinas (Inst), AstraZeneca (Inst), AtlasMedx (Inst), BeiGene (Inst), Black Diamond Therapeutics (Inst), Bliss Biopharmaceutical (Inst), Boehringer Ingelheim (Inst), Bristol-Myers Squibb (Inst), Cascadian Therapeutics (Inst), Clovis Oncology (Inst), Compugen (Inst), Context Therapeutics (Inst), Cullinan Oncology (Inst), Curis (Inst), CytomX Therapeutics (Inst), Daiichi Sankyo (Inst), Dana-Farber Cancer Institute (Inst), Dantari (Inst), Deciphera (Inst), Duality Biologics (Inst), eFFECTOR Therapeutics (Inst), Eisai (Inst), Ellipses Pharma (Inst), Elucida Oncology (Inst), EMD Serono (Inst), Fochon Pharmaceuticals (Inst), Fujifilm (Inst), G1 Therapeutics (Inst), Genentech/Roche (Inst), Gilead Sciences (Inst), H3 Biomedicine (Inst), Harpoon (Inst), Hutchison MediPharma (Inst), Immunogen (Inst), Immunomedics (Inst), Incyte (Inst), Infinity Pharmaceuticals (Inst), Inspirna (Inst), InventisBio (Inst), Jacobio (Inst), K-Group Beta (Inst), Karyopharm Therapeutics (Inst), Kind Pharmaceuticals (Inst), Leap Therapeutics (Inst), Lilly (Inst), Loxo (Inst), Lycera (Inst), MabSpace Biosciences (Inst), Macrogenics (Inst), MedImmune (Inst), Mersana (Inst), Merus (Inst), Millennium (Inst), Molecular Templates (Inst), Myriad Genetics (Inst), Novartis (Inst), Nucana (Inst), Olema Pharmaceuticals (Inst), OncoMed (Inst), Oncothyreon (Inst), ORIC Pharmaceuticals (Inst), Orinove (Inst), Orum Therapeutics (Inst), Pfizer (Inst), PharmaMar (Inst), Pieris Pharmaceuticals (Inst), Pionyr (Inst), Plexxikon (Inst), Prelude Therapeutics (Inst), ProfoundBio (Inst), Radius Health (Inst), Regeneron (Inst), Relay Therapeutics (Inst), Repertoire Immune Medicines (Inst), Rgenix (Inst), Seagen (Inst), Sermonix Pharmaceuticals (Inst), Shattuck Labs (Inst), Silverback Therapeutics (Inst), Stem CentRx (Inst), Stemline Therapeutics (Inst), Sutro Biopharma (Inst), Syndax (Inst), Syros Pharmaceuticals (Inst), Taiho Pharmaceutical (Inst), TapImmune Inc. (Inst), Tesaro (Inst), Tolmar (Inst), Torque (Inst), Treadwell Therapeutics (Inst), Verastem (Inst), Zenith Epigenetics (Inst), and Zymeworks (Inst). Meisel disclosed consulting or advisory roles with AstraZeneca, GE Healthcare, Genentech, Novartis, Olema Oncology, Pfizer, SeaGen, Sermonix Pharmaceuticals, and Stemline, and research funding from AstraZeneca (Inst), Olema Oncology (Inst), Pfizer (Inst), Seagen (Inst), and Sermonix Pharmaceuticals (Inst). Grinshpun disclosed honoraria from GSK, Lilly, Novartis, and AstraZeneca, and travel from Roche, Pfizer, and AstraZeneca. Gradishar disclosed consulting or advisory roles with AstraZeneca , Genentech/Roche, Gilead Sciences, Merck, Novartis, Pfizer.

Transcript: Rep. Raja Krishnamoorthi on "Face the Nation with Margaret Brennan," June 1, 2025
Transcript: Rep. Raja Krishnamoorthi on "Face the Nation with Margaret Brennan," June 1, 2025

CBS News

time14 minutes ago

  • CBS News

Transcript: Rep. Raja Krishnamoorthi on "Face the Nation with Margaret Brennan," June 1, 2025

The following is the transcript of an interview with Rep. Raja Krishnamoorthi, Democrat of Illinois, that aired on "Face the Nation with Margaret Brennan" on June 1, 2025. MARGARET BRENNAN: We turn now to the top Democrat on the House Select Committee on the Chinese Communist Party, that's Congressman Raja Krishnamoorthi. He's in Illinois. Good morning to you. I want to get-- REP. KRISHNAMOORTHI: --Good morning. MARGARET BRENNAN: I want to get straight to it. You heard from the Secretary of State this week that the State Department is going to work with Homeland Security to aggressively revoke visas for Chinese students, including those with connections to the Chinese Communist Party or studying in critical fields. There are like 300,000 Chinese students with visas in this country. The U.S. government already has a heightened level of vetting. What's going to change? REP. KRISHNAMOORTHI: I don't know. There's not enough details, but what it looks like if they're targeting all people of Chinese origin who are on international student visas because he's not limiting it to just people who might have ties to the Chinese Communist Party, and if they do have those ties, they don't belong here, especially if they're committing nefarious acts. However, this appears to be much broader and it's terribly misguided and it appears prejudicial and discriminatory. My own father was, came here on an international student visa. And I believe that these people are vital for our economy and for entrepreneurship in this country. And I think this is going to harm America more than help. MARGARET BRENNAN: You said if someone has ties to the Chinese Communist Party they shouldn't be here. Does that mean all the, the students who are children of leaders, for example Xi Jinping's own daughter, shouldn't have been allowed here? REP. KRISHNAMOORTHI: Well, if they were engaged in nefarious activities and if they are somehow deeply connected to the CCP, I think that we should be very careful. But in this particular case, they're not only going after people who might fall in that category, but it's anybody who is from China, including Hong Kong by the way, where people are actually persecuted for various freedoms they're trying to exercise, and who come here seeking to exercise those freedoms. So this is a terrible, terribly misguided policy. MARGARET BRENNAN: The Biden administration did conduct heightened vetting, as you know, of Chinese students. Do you think that there is a legitimate argument for expanding this, that certain areas should just be off limits? REP. KRISHNAMOORTHI: I think that you should definitely have heightened vetting, especially in certain critical areas because we know that the CCP tries to steal, for instance, intellectual property or worse. But the way that this is currently structured looks very, very suspicious and you have to remember that the people that are cheering for this policy, what Marco Rubio had called for, is the Chinese Communist Party. Why? Because they want these people back. They want the scientists and the entrepreneurs and the engineers who can come and help their economy. And so we are probably helping them, as well as other countries, more than helping ourselves with this policy. MARGARET BRENNAN: The Defense Secretary is traveling in Asia right now and he said in a defense forum speech that Beijing is quote "concretely and credibly preparing to use military force." He said their military is rehearsing. Take a listen. PETE HEGSETH: Any attempt by Communist China to conquer Taiwan by force would result in devastating consequences for the Indo-Pacific and the world. There's no reason to sugar coat it. The threat China poses is real and it could be imminent. MARGARET BRENNAN: He did not say what the consequences would be. Are you encouraged by what appears to be a statement of support for allies? REP. KRISHNAMOORTHI: I am. I think what he's saying is largely correct, but I think the problem is at the same time he says that, either Donald Trump or even him or others say other things that push away our friends, partners and allies in the region and cause confusion. And so we need to be consistent and thoughtful with regard to our statements, and we need to be also very methodical about our actions in trying to curb military aggression by the Chinese Communist Party in the South China Sea and with regard to Taiwan. MARGARET BRENNAN: Since you track U.S. intelligence, I wanted to ask you if you have any insight into what appears to be the swarm of Ukrainian drones that has destroyed 40 Russian military aircraft deep inside Russian territory overnight. Sources are telling our Jennifer Jacobs that the White House wasn't aware that this attack was planned. What can you tell us about the level of US intelligence sharing with Ukraine right now and helping them with their targets? REP. KRISHNAMOORTHI: I don't want to get into classified information, but what I can say is that it's a little bit more strained in light of what Donald Trump has said recently. The one thing that I can also say is that Trump was right the other day to say that Putin is crazy in the way that he's going after civilian areas in Ukraine repeatedly, and so the Ukrainians are striking back. At the end of the day, the only way that we can bring these hostilities to an end is by strengthening the hand of the Ukrainians. Trump should, at this point, realize that Putin is playing him and aid the Ukrainians in their battlefield efforts. That's the best way to get to some type of armistice or truce at the negotiating table sooner rather than later. MARGARET BRENNAN: All right, Congressman Krishnamoorthi thank you for your insights today.

Elon Musk Doesn't Agree With Every Trump Administration Action
Elon Musk Doesn't Agree With Every Trump Administration Action

Forbes

time14 minutes ago

  • Forbes

Elon Musk Doesn't Agree With Every Trump Administration Action

Elon Musk—a key adviser to President Donald Trump who left his formal role in the government Friday—said in an interview with CBS News earlier in the week he thought criticism of his Department of Government Efficiency was 'unfair' and said he doesn't want to 'take responsibility for everything this administration's doing.' President Donald Trump speaks during a news conference with Elon Musk on May 30, 2025 inside the ... More Oval Office at the White House in Washington. During an interview with CBS News, Musk initially shied away from questions about the impact of Trump's tariffs on his businesses before openly discussing DOGE and what he said were 'unfair' criticisms. 'If there was some cut, real or imagined, everyone would blame DOGE,' Musk told CBS News' David Pogue. He went on to discuss the administration more broadly, saying, 'it's not like I agree with everything the administration does … So it's like, I mean, I agree with much of what the administration does. But we have differences of opinion.' Musk said he doesn't want to 'take responsibility for everything this administration's doing,' but if he brought up his disagreements publicly it 'creates a bone of contention,' saying, 'I'm a little stuck in a bind.' On Tuesday, CBS News released a clip of the interview in which Musk criticized the 'big, beautiful bill' Trump has been advocating for in Congress. The clip showed Musk saying he was 'disappointed' about the bill, which he said 'increases the budget deficit, not just decreases it, and undermines the work that the DOGE team is doing.' The comments quickly made headlines, and the following day Musk confirmed his official departure from the government. Musk endorsed Trump and became a megadonor after an assassination attempt on the president while he was campaigning in July, and Musk ended up giving more than $200 million to help Trump get elected. After he won a second term in November, Trump announced Musk would lead the Department of Government Efficiency, which the president said would 'slash excess regulations, cut wasteful expenditures, and restructure Federal Agencies.' Musk became a special government employee—which limited his service term to 130 days—when Trump was inaugurated, and he began the work of slashing the federal workforce and spending. DOGE's work—which included laying off hundreds of thousands of federal employees—drew bipartisan criticism and a number of legal challenges that are still playing out in court. Trump regularly praised Musk, though, and Friday when the pair were discussing Musk's government departure, Trump thanked Musk for the 'colossal change' DOGE spearheaded and said he thinks Musk will continue helping the government. 'I'll continue to be visiting here and be a friend and adviser' to Trump, Musk said Friday at a press conference with the president. $2 trillion. That's initially how much Musk said DOGE would save the government, though he later lowered the estimate to $1 trillion. DOGE's website claims it has so far saved the government an estimated $175 billion, though the website has frequently featured errors like counting contracts multiple times, using 'billions' when it meant to report 'millions,' and more, according to The New York Times. A reporter from CNN estimated last week that less than half of the $175 billion figure is supported with documentation on DOGE's sites. Trump privately questioned whether Musk and DOGE could follow through on the amount of cuts they said they would make, according to a report in The Wall Street Journal Saturday. Unnamed officials in the administration told the Journal Trump asked, 'was it all bullshit?' and wondered if Musk could actually cut $1 trillion in government spending. Forbes estimates Musk has a net worth of about $422.7 billion as of Sunday morning, making him the wealthiest person in the world. Trump Defends Spending Bill After Musk Says It 'Undermines' DOGE Cuts (Forbes) Elon Musk on DOGE and why he doesn't want to "take responsibility for everything the administration's doing" (CBS News) Trump Defends Spending Bill After Musk Says It 'Undermines' DOGE Cuts (Forbes) Trump Questioned Extent Of Musk's DOGE Cuts, Report Says (Forbes)

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store